NCT00926380View on ClinicalTrials.gov

Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis

PHASE2CompletedINTERVENTIONAL

Enrollment

94

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions

Osteoporosis

Interventions

DRUG

denosumab

denosumab: 60 mg SC every 6 months

DRUG

teriparatide

teriparatide: 20 mcg SC QD

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Amgen

INDUSTRY

lead

Massachusetts General Hospital

OTHER